cryoprecipitate
Cryoprecipitate, also called cryo for short, or Cryoprecipitate Antihemophilic factor (AHF), is a frozen blood product prepared from blood plasma. To create cryoprecipitate, plasma is slowly thawed to 1–6 °C. A cold-insoluble precipitate is formed, which is collected by centrifugation, resuspended in a small amount of residual plasma and then re-frozen for storage. Cryoprecipitate contains fibrinogen, Factor VIII, Factor XIII and vWF. In many clinical contexts, use of cryoprecipitate has been replaced with use of clotting factor concentrates, but the whole form is still routinely stocked by many hospital blood banks. Cryo can be stored at −18 °C or colder for 12 months from the original collection date or up to 36 months in Europe if stored below -25 °C. After thawing, single units of cryo can be stored at 20–24 °C for up to 6 hours. If units of cryo are pooled in an open system, they can only be held at 20–24 °C for up to 4 hours. Presently cryo cannot be re-frozen for storage after it is thawed for use if it is not transfused. — Wikipedia
Clinical trial activity
9 trials · 20 clinical orgs · 0 marketing orgs
Earliest trial started Jan 31, 2017 (NCT04704869)
Timeline
Indications
Approved for
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCryoprecipitate ↗
Also known as
- cryoprecipitate
- ffp
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06617897 | Phase 3 | Sep 30, 2024 | CSL Behring |
| NCT05711524 | Phase 4 | Apr 1, 2023 | Cerus Corporation, Cornell University |
| NCT05449834 | Phase 3 | Oct 1, 2022 | Australasian College for Emergency Medicine, Australasian Trauma Society, Australian and New Zealand Intensive Care Society Clinical Trials Group, Australian Red Cross, Monash University |
| NCT04376762 | Phase 4 | Sep 1, 2020 | Octapharma, University of Virginia |
| NCT03932240 | Phase 3 | Jul 31, 2019 | Emory University |
| NCT03784794 | N/A | Nov 1, 2018 | Grupo Mexicano para el Estudio de la Medicina Intensiva |
| NCT03508141 | Phase 2 | Jun 1, 2018 | Australian Red Cross, Emergency Medicine Foundation, Griffith University, Lady Cilento Children's Hospital, National Blood Authority |
| NCT03045068 | N/A | Apr 11, 2017 | University of Texas at Houston |
| NCT04704869 | Phase 3 | Jan 31, 2017 | Baylor University, NHS Blood and Transplant, University of London, University of Texas at Houston |